Does Myomectomy for Intramural Fibroid Improve ART Outcome?

NCT ID: NCT03796130

Last Updated: 2019-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-01

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intamural fibroids (myoma) do exist in some infertile women undergoing IVF treatment. There is controversy whether myomectomy before IVF treatment could improve IVF outcome. This trial will examine whether myomectomy in those patients could improve the results.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will include women who have intramural myoma ranging from 3-5 cm

The participants will be randomly allocated into two groups.

In group (1): myomectomy will be performed before ART

In group (2):women will have their trial of ART without myomectomy

In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibroid Uterus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

(A)Myomectomy

This study will include women who have intramural myomas ranging from 3-5 cm

The participants will be randomlyallocated intotwo groups.

In group (A): myomectomy will be performed before ART

In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery

Group Type EXPERIMENTAL

Myomectomy

Intervention Type PROCEDURE

This study will include women who have intramural myomas ranging from 3-5 cm

The participants will be randomly allocated into two groups.

In group (1): myomectomy will be performed before ART

In group (2):women will have their trial of ART without myomectomy

In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery

(B) No myomectomy

This study will include women who have intramural myomas ranging from 3-5 cm

The participants will be randomly allocated into two groups.

In group (B):women will have their trial of ART without myomectomy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myomectomy

This study will include women who have intramural myomas ranging from 3-5 cm

The participants will be randomly allocated into two groups.

In group (1): myomectomy will be performed before ART

In group (2):women will have their trial of ART without myomectomy

In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women with intramural fibroid without any cavity involvement
* Age ˂ 35 years
* I onCSI or IVF cycles
* normal uterine cavity

Exclusion Criteria

* low ovarian reserve (AFC \< 7 and or AMH \< 1.1 ng/ml)
* Endometrioma
* Untreated hydrosalpinx
* Non obstructive azoospermia
* Any other cavitary lesions (Asherman syndrome, Mullerian anomalies)
* recurrent implantation failure
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alexandria University

OTHER

Sponsor Role collaborator

Zagazig University

OTHER_GOV

Sponsor Role collaborator

Sohag University

OTHER

Sponsor Role collaborator

Assiut University

OTHER

Sponsor Role collaborator

Mansoura University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Gibreel

Assistant professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed Gibreel, MD

Role: PRINCIPAL_INVESTIGATOR

Mansoura University

Mohamed S Abdelhafez, MD

Role: STUDY_DIRECTOR

Mansoura University

Salah Rasheed, MD

Role: STUDY_DIRECTOR

Sohag University

Ahmed Nasr, MD

Role: STUDY_DIRECTOR

Assiut Universit

Hisham A Saleh, MD

Role: STUDY_DIRECTOR

Alexandria University

Hassan El Maghraby, MD

Role: STUDY_DIRECTOR

Alexandria University

Eman El Gindy, MD

Role: STUDY_CHAIR

Zagazig University

Hoda Sibai, MD

Role: STUDY_DIRECTOR

Zagazig University

Hamed Yossef, MD

Role: STUDY_CHAIR

Mansoura University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mansoura University Hospital

Al Mansurah, Dakahlia Governorate, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eman ElGindy, MD, PhD

Role: CONTACT

Phone: 01227491143

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H0008

Identifier Type: -

Identifier Source: org_study_id